INTRODUCTION
Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders characterized by ineffective hematopoiesis, myelodysplasia and variable numbers of blasts. 1, 2 In the 2008 World Health Organization (WHO) classification system for hematologic neoplasms, MDS is classified into five major subtypes. 3 One of the subtypes, refractory cytopenia with multilineage dysplasia (RCMD) is characterized by multilineage dysplasia, pancytopenia in the peripheral blood, o5% blasts in the bone marrow and o1% blasts in the blood. Although some RCMD patients have clonal cytogenetic abnormalities, nearly half have a normal karyotype. 4 Given this heterogeneity, the various subtypes of MDS may reflect molecularly distinct entities that result from different molecular mechanisms and/or evolution of varying molecular abnormalities. Cytogenetically normal RCMD (CN-RCMD) provides ideal materials to study epigenetic dysregulation of myelopoiesis in MDS at an early stage prior to an overt blastic transformation. The morphologic feature of multilineage dysplasia in RCMD suggests dysregulation of the cell lineage development at the early stage of myelopoiesis that is tightly regulated by several key transcription factors including RUNX1, PU.1, GATA-1 and CEBPs. 5, 6 Among the key transcription factors, PU.1 is critical for myelopoiesis, especially for determining erythroid/megakaryocytic vs lymphoid/myeloid differentiation. [6] [7] [8] [9] [10] [11] [12] Reciprocal activation of GATA-1 and PU.1 determines the initial specification of hematopoietic stem cells (HSCs) into myeloerythroid vs myelolymphoid lineages. 13 A subtle change in PU.1 expression level can alter the differentiation of HSCs into erythrocytes, megakaryocytes monocytes, granulocytes or lymphocytes lymphoid lineages. [6] [7] [8] [9] [10] [11] [12] [13] While PU.1 is important in hematopoiesis, a suitable chromatin environment is equally important for PU.1 and other transcription factors to function properly. For instance, H3K27me3 carried out by EZH1/2 in the polycomb repression complex can cause chromatin condensation, resulting in gene silencing.
14 H3K27me3 and EZH1/2 have been shown to be important in modulating self-renewal and differentiation of HSCs. 15, 16 Although the importance of H3K27me3 and PU.1 in the regulation of differentiation of HSCs is well documented, very few studies have investigated the role of H3K27me3 and the interplay between H3K27me3 and PU.1 in MDS at the genome-wide level. To fill this void, we employed morphology/ cytogenetics-guided epigenetic profiling to analyze H3K27me3 alterations, along with the recruitment of PU.1 and EZH2, at the genome-wide scale. Our computational analysis showed a genome-wide enrichment of the PU.1 DNA-binding motif in the regions with increased H3K27me3. An inverse relationship was found between levels of H3K27me3 and the levels of PU.1-binding and its downstream gene expressions. Our data suggest that inactivation of PU.1 pathway by H3K27me3 may have a contributory role in CN-RCMD. We also performed whole-exome Mononuclear cells were isolated from the 10 CN-RCMD bone marrow specimens (Table 1 ) and 10 age-/sex-matched normal bone marrow specimens by using Ficoll gradient Histopaque-1077 (Sigma no. 1077-1) according to the manufacturer's protocol. Five million mononuclear cells from each CN-RCMD patient or normal patient were used to perform a single regular ChIP. For ChIP-on-chip, 30-40 million mononuclear cells were pooled from the 10 CN-RCMD and normal bone marrows to obtain a sufficient amount of ChIPed DNA for the NimbleGen whole-genome promoter analysis (Roche NimbleGen, Madison, WI, USA). We modified the original protocol developed by Ren et al., 19 by introducing a new elution buffer and procedure to allow quantitative PCRs to be performed directly on the eluates without additional purification. Briefly, DNA/protein complexes from CN-RCMD and normal bone marrow cells were crosslinked, fragmented and immunoprecipitated by specific antibodies. The immunoprecipitated DNA was purified, amplified by blunt-ended ligationmediated PCR and then labeled with C5 and C3 fluorescent dyes, respectively. The labeled DNA samples were hybridized simultaneously to a NimbleGen genomic promoter array that contains 720 000 probes and covers 22 542 promoters per array (calculated on the basis of transcription start sites). The probability of a particular base occuring in the motif was determined by counting the number of occurrences of the base and dividing by N, the total number of bases in the DNA sample. For example, the average overrepresentation of the PU.1 motif was calculated by O a ¼ [ Drug inhibition assays of cell proliferation assays and determination of cell viability
Cells were seeded into 96-well plates at a density of 2 Â 10 4 cells/ml. A 10mM stock solution of each inhibitor was prepared in dimethyl sulfoxide. These inhibitors were further diluted in media and immediately added to the 96-well plates. Beginning at 24 h after inhibitor addition and at 24 h intervals, cell density was determined using a Coulter counter to count triplicate wells. Cell viability was determined by microscopic inspection of Trypan Blue-stained cells.
Ectopic expression and cell transfection assay OCI-M2 cells were cultured to reach 70% confluency in Dulbecco's modified Eagle's medium. The cells were collected and replaced in serumfree medium for 6 h, and then transfected with appropriate amounts of the empty vector plasmid and the PU.1 expression plasmid (kindly provided by Dr Sung-su Kim), which was constructed by cloning the human PU.1 cDNA into the cytomegalovirus-driving vector. Lipofectamine LTX Reagent (Invitrogen, Catalog no. 15338030) was used to transfect the cells according to the manufacturer's protocol. The transfected cells were grown in the completed Dulbecco's modified Eagle's medium for 24-48 h. The cell growth rate and the PU.1 mRNA expression were measured by Coulter counting and RT-PCR, respectively.
Immunohistochemistry, flow cytometry and apoptosis assay For immunohistochemistry, the immunostain for PU.1 was performed in the Department of Pathology at the UMMC. Briefly, the bone marrow 
RESULTS
Genome-wide enrichment of the PU.1 DNA-binding site (motif) in the regions with increased H3K27me3 in CN-RCMD To compare the levels of H3K27me3 between the CN-RCMD cases and the normal controls at the genome-wide scale, we employed a morphology/cytogenetics-guided epigenetic approach, as shown in Figure 1 . Table 1 provides the clinical information on the 10 CN-RCMD cases. Figure 1a shows the bone marrow cell morphology of one representative case from the CN-RCMD cases. Figure 1b schematically illustrates the modified ChIP-on-chip with an anti-H3K27me3 antibody. Figure 1c shows the genome-wide H3K27me3 peaks that have higher levels of H3K27me3 in CN-RCMD above the normal controls. When 1.5-fold was used as the cutoff value, 12 560 H3K27me3 peaks were found at the whole genome-level, which were associated with 4626 annotated gene promoters. Further computational analysis revealed three DNA motifs that were two-fold more frequent than that expected by random chance in the regions with increased H3K27me3. Two of the identified motifs matched no known DNA-binding motifs in our multigenome computational analysis (data not shown here). However, one of the motifs contained an RRGGAASY sequence that matched the well-known PU.1 DNA-binding site (PU-box). 20, 21 Our gene ontology analysis showed that a large portion of the gene promoters containing the 'RRGGAASY' motif were involved in protein-protein interactions, DNA binding and gene regulation (Figure 1d ).
An inverse relationship existed between the levels of H3K27me3 in the regulatory regions of the PU.1 gene and its levels of mRNA and protein expressions in CN-RCMD To further illustrate the epigenetic dysregulation of PU.1 gene in CN-RCMD, we performed individual ChIP, real-time RT-PCR and immunohistochemical studies on all 10 CN-RCMD cases listed in Table 1 and the age-/sex-matched normal patient controls. Figure 2a schematically illustrates the major regulatory elements of SPI1, the PU.1-encoding gene. PU.1 binds to both its own promoter and its enhancer to activate its own gene expression. [22] [23] [24] Our individual ChIP experiments showed a significant increase in H3K27me3 at both the promoter and the enhancer of the PU.1 gene, with a more prominent increase in the distal enhancer in all 10 CN-RCMD cases, compared with that in the normal controls ( Figure 2b ). Our individual RT-PCRs showed that the PU.1 mRNA levels were significantly lower in all 10 CN-RCMD cases than those in the normal controls, as shown in Figure 2c . Our immunohistochemical studies showed that in the normal bone marrows, PU.1 protein expression varied greatly at various differential stages and in different lineages, and its expression increased during monocyte and granulocyte development with the lowest level in myeloid blasts/progenitors and the highest level in mature granulocytes and monocytes, as shown in the top panel of Figure 2d . PU.1 expression in erythroid precursors and megakaryocytes was undetectable by immunohistochemistry. Our immunohistochemical studies showed that 6 out of the 10 CN-RCMD cases had a marked loss of PU.1 expression, with a marked loss being arbitrarily set at when more than 20% of the segmented neutrophils were shown to be negative for PU.1 expression; two cases had a mild loss of PU.1 expression (10-20%) and another two cases had no appreciable loss of PU.1 expression (o10%). In contrast to the CN-RCMD cases, no loss of PU.1 expression was seen in the 10 normal controls.
Increased levels of H3K27me3 were inversely correlated with decreased levels of PU.1 binding to its target genes and their mRNA expression in CN-RCMD Our genome-wide analysis showed a significant increase in H3K27me3 at the promoters of almost all of the known PU.1 targeting genes that are important for myelopoiesis, as shown in Figure 3 . CCAAT/enhancer-binding protein a (CEBPA) and retinoic acid receptor a (RARA), two direct targets of PU.1, regulate the expression of many important myeloid genes. The genome-wide analysis showed increased H3K27me3 at the promoters of the CEBPA and RARA genes in CN-RCMD, compared with the normal control (Figures 3a and b) . Consistent with previous findings of epigenetic silencing of the p15/INK4B and the p16/INK4A genes by overexpression of EZH2 and BMI1 in myeloid neoplasms, 2,25-28 our genome-wide analysis also found an increase in H3K27me3 at the INK4A-INK4B locus (Figure 3c ). PU.1 directly regulates expressions of myeloid-specific cell surface and cytoplasmic proteins such as neutrophil elastase encoded by ELA2, CD18 and CD68. 11 Our genome-wide analysis data showed a significant increase in H3K27me3 at these PU.1 target gene promoters (Figures 3d, e  and f) . The individual ChIP experiments demonstrated a marked increase in H3K27me3 that is associated with a marked decrease in the binding of PU.1 to the promoters of the PU.1 target genes in all 10 CN-RCMD cases (Figures 3g and h) . Quantitative RT-PCRs demonstrated an inverse relationship between the levels of H3K27me3 and the levels of PU.1-binding and their mRNA expression at the promoters of the PU.1 target genes, suggesting that H3K27me3 blocks PU.1 binding to its target gene promoters and results in downregulation of the expressions of those genes in CN-RCMD.
H3K27me3 preferentially prevented PU.1 from binding to its downstream myeloid-specific genes at the genome-wide scale in CN-RCMD Our experiments showed an increase in H3K27me3, along with a decrease in PU.1-binding and gene expression of the PU.1 target genes in RCMD. These studies, however, did not address whether the reduction of PU.1-binding and gene expression could be simply due to globally reduced PU.1 expression rather than a result of increased H3K27me3 of the gene promoters. Here, we describe the experiments designed to address three questions: (1) whether H3K27me3 prevents PU.1 from binding to its targets including OCI-M2 cells, an erythroid/myeloid leukemia cell line derived from an MDS patient, 17 to various histone-modifying drugs ( Figure 5 ). The histone-modifying drugs used in this study include 3-deazaneplanocin A (DZNep), an inhibitor of S-adenosylhomocysteine hydrolase with a potent selectivity for H3K27me3 methyltransferase, 29, 30 Panobinostat, a pan-histone deacetylase inhibitor with a selective inhibition for EZH2 and H3K27me3, 31 and Bix-1294, a diazepin-quinazolin-amine derivative that can specifically inhibit the histone H3 lysine 9 (H3K9) methyltransferases, G9a and G9a-like protein. 32 We also studied the relationship between growth inhibition and the PU.1 expression in various lines, because the expression level of PU.1, the key factor in determining myeloid lineage specification, varies significantly in different lineage lines (see Supplementary Figure  S1 in the Supplementary Material). Figures 5a and b show that the H3K27me3 inhibitors, DZNep and panobinostat, could effectively inhibit the proliferation of OCI-M2 cells. Unlike DZNep and PA, Bix-1294 showed no significant inhibitory effects on the proliferation of the OCI-M2 cells with the dosage higher than those reported previously in various cell lines 32 ( Figure 5c ). We also studied the effect of ATRA because ATRA is known to induce granulocytic differentiation in NB4 cells via a PU.1-mediated mechanism. (Figure 6c ), as well as by morphologic evaluation (Figure 5f ).
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We also performed drug-inhibition experiments with DZNep on the primary bone marrow cells of three cytogenetically normal MDS patients. Consistent with the results from the MDS-derived cell line, DZNep (1.0 mM) induced B4-to 32-fold increase in PU.1 in the primary bone marrow cells from patients with MDS and induced an approximately 4-to 6-fold increase in CD18 expression, a granulocytic/myeloid differentiation marker, in these clinical specimens (Figures 6d and e) . Furthermore, DZNep could also induce expressions of other PU.1 target genes in the primary MDS bone marrow cells, namely CEBPA, ELANE, CD68 and CSF1R, in the MDS primary bone marrow cells (data not shown).
Enforced PU.1 expression inhibiting the growth of the MDSderived erythroid/myeloid cell line and a hypothetical model for epigenetic deregulation of the PU.1 pathway in CN-RCMD To further demonstrate the extent to which the downregulation of PU.1 expression contributes to the abnormal proliferation of erythroid/myeloid cells in MDS, we enforced PU.1 expression using a cytomegalovirus promoter-driving PU.1 expression vector in the OCI-M2 line that has a very low level of PU.1 expression. A significant growth inhibitory effect was observed with the ectopic PU.1 expression vector, but not with the empty vector (Figures 7a  and b) . The RT-PCRs showed an approximately six-fold increase in PU.1 mRNA expression in the cells transfected with the PU.1 expression vector (data not shown). Conversely, knocking down PU.1 expression by si-RNA showed no inhibitory effects on the proliferation of the MDS-derived erythroid/myeloid cell line (data not shown here). Recent studies have identified two pathways, a classical bifurcation pathway and an alternative lymphoid/myeloid potent progenitor (LMPP) pathway in both normal hematopoiesis and leukemogenesis, 34, 35 and PU.1 has a key role in the control of the LMPP pathway (Figure 7c ). Based on our data, we propose a Table S4 ) that may be relevant to the genetic or epigenetic dysregulation of PU.1/ LMPP pathway or possible pathogenetic mechanisms in the CN-RCMD cases.
DISCUSSION
MDS comprises morphologically distinct groups of hematologic disorders likely caused by different underlying molecular mechanisms and may require different targeting therapies. Therefore, it is important to define the molecular pathogenesis in various subtypes of MDS. We reported our initial results of genome-wide epigenetic profiling of DNA and histone (H3K27) methylation in RCMD, 36 which to our knowledge was the first such report focused on MDS or leukemia. Our initial genome-wide epigenetic profiling and expression analysis showed a strong inverse correlation between the levels of myeloid gene expression and the level of H3K27me3, but not DNA methylation, at the gene promoters in CN-RCMD. To explore this further, we focused on H3K27me3 in this study. In our experience, genome-wide analysis of histone modifications in clinical specimens is technically much more difficult than analysis of DNA methylation or mutations because histone modifications are much more unstable and very sensitive to any changes in experimental procedures, cell conditions and reagents. In addition, a large number of intact mononuclear cells are required for ChIP-on-chips. Consequently, very few genome-wide studies of histone modification alterations have been conducted on clinical MDS specimens.
Our genome-wide epigenetic profiling showed a statistically significant enrichment of the PU.1 motif (PU-box) in the regions with increased H3K27me3 in CN-RCMD (Figure 1) . Importantly, increased H3K27me3 preferentially occurs at the PU.1-targeting myeloid genes in CN-RCMD (Figures 3 and 4) . To our surprise, EZH2, a well-known H3K27 methyltransferase, was absent from the majority of the myeloid gene promoters with increased H3K27me3, which we speculated could be due to a 'hit-and-run' phenomenon or other histone methyltransferase(s) involved in conducting the trimethylation reaction. Currently, the role of EZH2 in the pathogenesis of myeloid neoplasms remains controversial. The oncogenic features of EZH2, including overexpression and activating mutations, have been well documented in many solid tumors and B-cell lymphomas as well as in myeloid neoplasms such as MDS and AML. 27, 37 However, deletion and somatic-inactivating mutations in the EZH2 gene have also been reported in several myeloid neoplasms including MDS. 38, 39 Given conflicting data on EZH2 in myeloid neoplasms, it is likely that both inactivation and hyperactivation of EZH2 could be involved in various subgroups of myeloid neoplasms. We performed wholeexome sequencing and Sanger sequencing on all 10 CN-RCMD cases to identify possible genetic alterations that may account for the epigenetic dysregulation of the PU.1 pathway. As heterozygous mutations/deletions of the regulatory regions of PU.1 gene were reported in a small subset of AML cases previously, 40 we also performed Sanger sequencing analysis of the PU.1 regulatory regions, but no such mutations/deletions were identified in the CN-RCMD cases. The exome-sequencing analysis did not reveal any mutations in the coding regions of EZH1/2 genes. Interestingly, RUNX1, which encodes, a key transcription factor directly regulating PU.1 expression, 41 was found to be mutated in three out of six cases of CN-RCMD (see the Supplementary Material Table 4S ). Currently, we are actively analyzing the mutations identified in each morphologically distinct subtype of MDS, which is beyond the scope of this study.
The results from our genome-wide ChIP-on-chip, individual ChIP, H3K27me3 inhibitor and ectopic PU.1 expression experiments strongly argue for the importance of H3K27me3 in the inactivation of the PU.1 pathway in CN-RCMD. It appears that the mechanism is one where PU.1 is prevented from binding to its myeloid-specific targets. Our finding of considerable differences in the response of the MDS-derived cells to various histonemodifying drugs reinforces the importance of defining the molecular pathogenesis underlying those morphologically and clinically distinct myeloid neoplasms. Given the critical role of PU.1 in myelopoiesis, especially in the newly proposed LMPP pathway, [6] [7] [8] [9] [10] [11] [12] 34, 35 and our data demonstrating inactivation of the PU. 
